Retatrutide (Reta): The Complete Guide (2026)

What Is Retatrutide?

Retatrutide (also known as Reta or by its research designation LY3437943) is an investigational triple hormone receptor agonist developed by Eli Lilly and Company. Unlike single-agonist peptides such as semaglutide, Retatrutide activates three distinct receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor.

This triple-agonist mechanism sets Retatrutide apart from other compounds in the incretin-based peptide class. Tirzepatide, for example, is a dual GLP-1/GIP agonist, while Retatrutide adds glucagon receptor activation as a third pathway. Early-phase clinical trial data has generated significant interest in its potential for weight management and metabolic health research.

Retatrutide is currently in clinical trials and is not approved by the FDA for any medical use. It remains an investigational compound, and all information presented here is based on published research and clinical trial data available to date.

How Does Retatrutide Work?

Retatrutide's mechanism of action is based on simultaneously activating three hormone receptors that play key roles in metabolism, appetite regulation, and energy expenditure. This triple-agonist approach is what researchers believe may give it a differentiated profile compared to single or dual agonists.

GLP-1 Receptor Agonism

GLP-1 (glucagon-like peptide-1) is a gut hormone that plays a central role in blood sugar regulation and appetite control. By activating the GLP-1 receptor, Retatrutide is believed to help reduce appetite, slow gastric emptying, and improve insulin secretion in response to food intake. This is the same receptor targeted by semaglutide and liraglutide.

GIP Receptor Agonism

GIP (glucose-dependent insulinotropic polypeptide) is another incretin hormone that enhances insulin secretion and may influence fat metabolism. Research suggests that GIP receptor activation may complement GLP-1 effects, potentially contributing to greater metabolic improvements than GLP-1 agonism alone. This dual incretin approach is also utilized by tirzepatide.

Glucagon Receptor Agonism

The glucagon receptor component is what makes Retatrutide unique among currently investigated incretin-based therapies. Glucagon is a hormone that promotes energy expenditure, stimulates fat breakdown (lipolysis), and may help reduce liver fat. Research suggests that glucagon receptor activation could increase resting metabolic rate, potentially enhancing the overall metabolic effects beyond what GLP-1 and GIP agonism achieve on their own.

The Triple-Agonist Advantage

By engaging all three receptors simultaneously, Retatrutide is hypothesized to address weight management and metabolic health through multiple complementary pathways: appetite reduction via GLP-1, improved insulin function via GIP, and increased energy expenditure via glucagon signaling. Clinical trial data published to date appears to support this multi-pathway approach, though larger Phase 3 trials are needed to confirm these findings.

Potential Benefits

The following potential benefits are based on published clinical trial data and preclinical research. Retatrutide is an investigational compound, and these findings should not be interpreted as guaranteed outcomes. Larger confirmatory trials are ongoing.

Weight Management Research

Phase 2 clinical trial data published in 2023 reported significant weight reduction in participants receiving Retatrutide over a 48-week period. Research subjects in the highest dose groups experienced substantial changes in body weight compared to placebo. These results generated considerable interest in the research community, as the magnitude of weight change appeared to be among the highest reported for any single investigational agent in this class.

Metabolic Effects

Clinical trial data suggests Retatrutide may have favorable effects on several metabolic markers. Research indicates potential improvements in blood glucose regulation, insulin sensitivity, and lipid profiles in trial participants. The triple-agonist mechanism is believed to address metabolic dysfunction through multiple pathways simultaneously.

Appetite Regulation

Through its GLP-1 receptor activation, Retatrutide appears to significantly reduce appetite and food intake in clinical trial participants. Studies indicate that the compound may slow gastric emptying and promote satiety, which are key factors in sustained weight management. The combination with GIP agonism may further enhance these effects.

Potential Liver Fat Reduction

One of the most notable findings from early Retatrutide research relates to liver fat. The glucagon receptor activation component is believed to contribute to hepatic fat reduction. Published clinical data has reported significant decreases in liver fat content among trial participants, which has prompted further investigation into Retatrutide's potential role in metabolic-associated liver conditions. This area of research is ongoing.

Energy Expenditure

The glucagon receptor agonist component of Retatrutide is theorized to increase resting energy expenditure. Unlike compounds that rely solely on appetite suppression, research suggests Retatrutide may also promote caloric expenditure through thermogenic and lipolytic pathways. This dual approach — reduced intake combined with increased expenditure — is a key area of interest for researchers studying the compound.

Dosage Guidelines

Disclaimer: The following information is based on published clinical trial protocols and research data. This is not medical advice. Retatrutide is an investigational compound not approved for human use. Always consult a healthcare professional.

Clinical Trial Protocols

In Phase 2 clinical trials, Retatrutide was administered as a once-weekly subcutaneous injection. Published trial data examined several dose levels, with participants typically undergoing a dose-escalation protocol to improve tolerability. Doses studied in clinical trials have ranged from 0.5mg to 12mg per week, with escalation occurring over the initial weeks of the study period.

Dose Escalation Approach

Clinical trial protocols for Retatrutide employed a gradual dose-escalation strategy. Participants did not begin at the target dose but instead started at a lower dose and increased incrementally over several weeks. This approach is consistent with other GLP-1 receptor agonists and is designed to help minimize gastrointestinal side effects during the initial period of use.

• Starting doses: Clinical trials typically initiated treatment at lower doses (e.g., 0.5mg weekly) before escalating.
• Escalation schedule: Dose increases occurred at defined intervals, commonly every 4 weeks, until the target maintenance dose was reached.
• Maintenance doses: The higher dose groups in published trials reached maintenance doses of up to 12mg per week.

Administration

In clinical trials, Retatrutide was administered via once-weekly subcutaneous injection. The weekly dosing schedule is similar to other long-acting incretin-based therapies and is considered a practical advantage for adherence compared to daily dosing protocols.

Side Effects & Safety

Safety data for Retatrutide comes primarily from Phase 1 and Phase 2 clinical trials. While initial data has been informative, comprehensive long-term safety data from large-scale Phase 3 trials is still being collected.

Gastrointestinal Side Effects

Consistent with other GLP-1 receptor agonists, the most commonly reported side effects in Retatrutide clinical trials were gastrointestinal in nature. These include:

• Nausea: The most frequently reported side effect, particularly during the dose-escalation phase. Incidence appeared to decrease over time as participants adjusted to the compound.
• Diarrhea: Reported in a subset of trial participants, generally mild to moderate in severity.
• Vomiting: Occurred in some participants, most commonly in the higher dose groups during escalation.
• Decreased appetite: While considered a therapeutic effect, significant appetite reduction was noted as a common occurrence.
• Constipation: Reported in some participants, likely related to slowed gastric motility.

Dose-Dependent Side Effects

Clinical trial data suggests that side effect frequency and severity tended to increase with higher doses of Retatrutide. The dose-escalation protocol used in trials was specifically designed to mitigate this by allowing the body to gradually adjust. Most gastrointestinal side effects were reported as mild to moderate and transient.

Important Safety Considerations

• Not FDA-approved: Retatrutide is an investigational compound currently in clinical trials. It is not approved for human use by the FDA or any other regulatory agency.
• Limited long-term data: Published safety data covers trial periods of up to 48 weeks. The long-term safety profile over years of use has not been established.
• Contraindications: Clinical trials excluded participants with certain medical conditions. The safety of Retatrutide in populations such as pregnant or nursing individuals, those with a personal or family history of medullary thyroid carcinoma, or those with severe gastrointestinal disease has not been established.
• Drug interactions: The effects of Retatrutide in combination with other medications, including other weight management compounds, have not been thoroughly studied.
• Research compound availability: Retatrutide obtained outside of clinical trials has not undergone the same manufacturing and quality controls. Purity and dosing accuracy from non-clinical sources cannot be guaranteed.

Where to Buy Retatrutide

Retatrutide is an investigational compound available through the research peptide market. Because it is not FDA-approved, sourcing from a reputable vendor with verified third-party testing is essential. Below are our top recommended vendors for 2026, evaluated on purity, independent lab testing, pricing, and customer service.

Disclosure: This page contains affiliate links. If you purchase through our links, we may earn a commission at no extra cost to you. This helps support our independent research and content. We only recommend vendors we have vetted and trust.

Frequently Asked Questions